88812-95-7Relevant academic research and scientific papers
The new compound and its in the treatment of inflammation or inflammation-related application (by machine translation)
-
Paragraph 0166-0169, (2018/12/13)
The present invention provides novel compounds and their use in the treatment of inflammation or inflammation-related diseases of application, in particular, the invention synthesizes a series of UTLOH compound, the compound can be effectively inhibit LPS-induced PGE2 and NO level, but also can be effective for the treatment of inflammation or inflammation-related disease, particularly for the treatment of Gout, analgesic and anti-inflammatory related diseases. (by machine translation)
Isoxazole derivatives and methods of treating nitric oxide mediated diseases
-
Page/Page column 4-5, (2008/06/13)
A series of isoxazole derivatives and methods of suppressing, inhibiting, or preventing disorders mediated by nitric oxide (NO) and/or proinflammatory cytokines, such as TNF-α (tumor necrosis factor alpha), IL-1 (interlukin-1), and IL-6, are described.
New N-aryl isoxazolecarboxamides and N-isoxazolylbenzamides as anticonvulsant agents
Lepage,Tombret,Cuvier,Marivain,Gillardin
, p. 581 - 593 (2007/10/02)
We prepared a series of N-aryl isoxazolecarboxamide, N-isoxazolylbenzamide compounds and derivatives and studied their anticonvulsant action in MES and MMS tests. Some of these reveal considerable activity, especially with respect to MES test. The disubstitution in the 2.6-position on the phenyl ring by two methyl groups would appear to be of primary importance for the activity. The amide bridge between the phenyl and isoxazolic rings, whether of the anilide or benzamide type, seems to show similar anticonvulsant behavior. We have selected the derivatives 8 (N-(2.6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide, 12 (N-(2.6-dimethylphenyl)-5-hydroxymethyl-3-isoxazolecarboxamide) and 51 (N-(5-methyl-3-isoxazolyl)-2.6-dimethylbenzamide) which are presently being studied in more extended pharmacological tests.
